Technical Analysis for CBAY - CymaBay Therapeutics Inc.

Grade Last Price % Change Price Change
A 32.46 0.03% 0.01
CBAY closed up 0.03 percent on Monday, March 18, 2024, on 81 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
7 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Flat

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 26.35%
New Uptrend Bullish 26.35%
New 52 Week High Strength 26.35%
MACD Bullish Signal Line Cross Bullish 30.05%
New 52 Week Closing High Bullish 30.05%
Pocket Pivot Bullish Swing Setup 30.05%
Bollinger Band Squeeze Range Contraction 30.05%
New 52 Week High Strength 30.05%
BB Squeeze + Upper Band Touch Range Contraction 30.05%
Above Upper BB Strength 30.05%

   Recent Intraday Alerts

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

CymaBay Therapeutics Inc. Description

Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. Its lead product candidate is Arhalofenate, which completed five Phase II clinical trials for the treatment of gout. The company's product candidate also includes MBX-8025, a selective agonist that is in a Phase II clinical trial in patients with mixed dyslipidemia; and MBX-2982, an oral, G-protein coupled receptor agonist to treat type II diabetes. Cymabay Therapeutics, Inc. has a development and license agreements with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of T2DM and other disorders; and a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products. The company was formerly known as Metabolex, Inc. Cymabay Therapeutics, Inc. was incorporated in 1988 and is based in Newark, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Diabetes Health Care Disorders Therapeutic Products Lipid Metabolic Disease Regulus Therapeutics Dyslipidemia Type I Diabetes Type II Diabetes Gout Mixed Dyslipidemia

Is CBAY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 32.48
52 Week Low 7.2609
Average Volume 4,263,780
200-Day Moving Average 18.07
50-Day Moving Average 28.06
20-Day Moving Average 32.31
10-Day Moving Average 32.38
Average True Range 0.31
RSI (14) 81.10
ADX 67.74
+DI 42.03
-DI 5.94
Chandelier Exit (Long, 3 ATRs) 31.54
Chandelier Exit (Short, 3 ATRs) 33.06
Upper Bollinger Bands 32.51
Lower Bollinger Band 32.10
Percent B (%b) 0.87
BandWidth 1.29
MACD Line 1.19
MACD Signal Line 1.49
MACD Histogram -0.3035
Fundamentals Value
Market Cap 3.68 Billion
Num Shares 113 Million
EPS -0.93
Price-to-Earnings (P/E) Ratio -34.90
Price-to-Sales 117.35
Price-to-Book 8.94
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 32.51
Resistance 3 (R3) 32.51 32.49 32.50
Resistance 2 (R2) 32.49 32.48 32.49 32.49
Resistance 1 (R1) 32.48 32.47 32.48 32.48 32.49
Pivot Point 32.46 32.46 32.46 32.46 32.46
Support 1 (S1) 32.45 32.45 32.45 32.45 32.43
Support 2 (S2) 32.43 32.44 32.43 32.43
Support 3 (S3) 32.42 32.43 32.42
Support 4 (S4) 32.42